Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 4/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6368604 | 0.83 | DRD2 (0.58) | ACKR3CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL18918197 | 0.81 | KDM4E (0.43) | — | |
| SCHEMBL31578827 | 0.80 | HTR7 (0.53) | ACKR3CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL17294058 | 0.77 | CYP2A6 (0.44) | CYP2A6DRD2PLA2G4ACNR2 | |
| SCHEMBL18918073 | 0.76 | CYP2A6 (0.43) | CYP2A6DRD2PLA2G4A | |
| SCHEMBL31578902 | 0.76 | PLK1 (0.42) | ACKR3CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL1555415 | 0.76 | EPHX2 (0.57) | DRD2EPHX2 | |
| SCHEMBL18917677 | 0.75 | GPR119 (0.43) | CYP2A6 | |
| SCHEMBL15748133 | 0.75 | DRD2 (0.51) | CYP2A6DRD2DRD4DRD3 | |
| SCHEMBL3423418 | 0.75 | EPHX2 (0.47) | ACKR3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084466-B2 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-27 | — | — | US | disclosed |
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | KINDRACHUK DAVID E | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | HRH4, HRH3, HRH1 | ACKR3 317/4885CYP2A6 2457/4885CHRM2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.